PolyPeptide Group AGPolyPeptide Group AGPolyPeptide Group AG

PolyPeptide Group AG

No trades
See on Supercharts
Next report date
Report period
EPS estimate
Revenue estimate
Market capitalization
‪835.69 M‬CHF
−0.991CHF
‪−18.64 M‬CHF
‪320.83 M‬CHF
‪13.02 M‬
Beta (1Y)
1.33
Employees (FY)
‪1.36 K‬
Change (1Y)
+89 +6.99%
Revenue / Employee (1Y)
‪235.56 K‬CHF
Net income / Employee (1Y)
‪−13.68 K‬CHF

About PolyPeptide Group AG


CEO
Juan-José Gonzalez
Headquarters
Baar
Founded
1952
ISIN
CH1110760852
FIGI
BBG0100P02W2
PolyPeptide Group AG engages in the business of development, manufacturing, and marketing of peptide- and oligonucleotide-based compounds for use in the pharmaceutical and related research industries. It operates through the following business areas: Custom Projects, Contract Manufacturing, and Generics and Cosmetics. The Custom Projects business area includes manufacturing of custom research-grade peptides and oligonucleotides for use in pre-clinical and clinical development as well as for regulatory and scientific studies. The Contract Manufacturing business area focuses on peptides for commercial stage peptide therapeutics, at scale, in commercial batches and in accordance with current Good Manufacturing Practice (cGMP) requirements. The Generics and Cosmetics business area is involved in peptide-based generics for the human and veterinary market, produced on an industrial scale following cGMP guidelines. The company was founded in 1952 and is headquartered in Baar, Switzerland.

Check out other big names from the same industry as 8H0.
Performance
Revenue to profit conversion
Debt level and coverage
Earnings
Next:
Summarizing what the indicators are suggesting.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
An aggregate view of professional's ratings.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Displays a symbol's price movements over previous years to identify recurring trends.

Frequently Asked Questions


The current price of 8H0 is 24.963 CHF — it has decreased by −11.57% in the past 24 hours. Watch PolyPeptide Group AG stock price performance more closely on the chart.
Depending on the exchange, the stock ticker may vary. For instance, on BX exchange PolyPeptide Group AG stocks are traded under the ticker 8H0.
8H0 stock has fallen by −11.57% compared to the previous week, the month change is a 19.15% rise, over the last year PolyPeptide Group AG has showed a −27.18% decrease.
We've gathered analysts' opinions on PolyPeptide Group AG future price: according to them, 8H0 price has a max estimate of 44.13 CHF and a min estimate of 26.93 CHF. Watch 8H0 chart and read a more detailed PolyPeptide Group AG stock forecast: see what analysts think of PolyPeptide Group AG and suggest that you do with its stocks.
8H0 reached its all-time high on Jul 22, 2022 with the price of 50.208 CHF, and its all-time low was 14.385 CHF and was reached on Jan 22, 2024. View more price dynamics on 8H0 chart.
See other stocks reaching their highest and lowest prices.
8H0 stock is 13.08% volatile and has beta coefficient of 1.33. Track PolyPeptide Group AG stock price on the chart and check out the list of the most volatile stocks — is PolyPeptide Group AG there?
Today PolyPeptide Group AG has the market capitalization of ‪834.68 M‬, it has decreased by −7.19% over the last week.
Yes, you can track PolyPeptide Group AG financials in yearly and quarterly reports right on TradingView.
PolyPeptide Group AG is going to release the next earnings report on Mar 12, 2026. Keep track of upcoming events with our Earnings Calendar.
8H0 earnings for the last half-year are −0.80 CHF per share, whereas the estimation was −0.53 CHF, resulting in a −50.59% surprise. The estimated earnings for the next half-year are 0.29 CHF per share. See more details about PolyPeptide Group AG earnings.
PolyPeptide Group AG revenue for the last half-year amounts to ‪156.17 M‬ CHF, despite the estimated figure of ‪145.11 M‬ CHF. In the next half-year revenue is expected to reach ‪218.58 M‬ CHF.
8H0 net income for the last half-year is ‪−24.99 M‬ CHF, while the previous report showed ‪−7.72 M‬ CHF of net income which accounts for −223.78% change. Track more PolyPeptide Group AG financial stats to get the full picture.
As of Sep 16, 2025, the company has ‪1.36 K‬ employees. See our rating of the largest employees — is PolyPeptide Group AG on this list?
EBITDA measures a company's operating performance, its growth signifies an improvement in the efficiency of a company. PolyPeptide Group AG EBITDA is ‪23.80 M‬ CHF, and current EBITDA margin is 6.94%. See more stats in PolyPeptide Group AG financial statements.
Like other stocks, 8H0 shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade PolyPeptide Group AG stock right from TradingView charts — choose your broker and connect to your account.
Investing in stocks requires a comprehensive research: you should carefully study all the available data, e.g. company's financials, related news, and its technical analysis. So PolyPeptide Group AG technincal analysis shows the buy rating today, and its 1 week rating is neutral. Since market conditions are prone to changes, it's worth looking a bit further into the future — according to the 1 month rating PolyPeptide Group AG stock shows the neutral signal. See more of PolyPeptide Group AG technicals for a more comprehensive analysis.
If you're still not sure, try looking for inspiration in our curated watchlists.